Literature DB >> 23283188

Gene expressing profiling of iris melanomas.

J William Harbour1, David Wilson, Paul T Finger, Lori A Worley, Michael D Onken.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23283188      PMCID： PMC4354954          DOI： 10.1016/j.ophtha.2012.08.016

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  4 in total

1.  Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study.

Authors:  Samira Khan; Paul T Finger; Guo-Pei Yu; Lubna Razzaq; Martine J Jager; Rob J W de Keizer; Per Sandkull; Stefan Seregard; Daniel Gologorsky; Amy C Schefler; Timothy G Murray; Tero Kivelä; Gian Paolo Giuliari; Hugh McGowan; E Rand Simpson; Christine Corriveau; Sarah E Coupland; Bertil E Damato
Journal:  Arch Ophthalmol       Date:  2011-09-12

2.  Initial management and follow-up of melanocytic iris tumors.

Authors:  J W Harbour; J J Augsburger; R C Eagle
Journal:  Ophthalmology       Date:  1995-12       Impact factor: 12.079

3.  Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Devron H Char; James J Augsburger; Zelia M Correa; Eric Nudleman; Thomas M Aaberg; Michael M Altaweel; David S Bardenstein; Paul T Finger; Brenda L Gallie; George J Harocopos; Peter G Hovland; Hugh D McGowan; Tatyana Milman; Prithvi Mruthyunjaya; E Rand Simpson; Morton E Smith; David J Wilson; William J Wirostko; J William Harbour
Journal:  Ophthalmology       Date:  2012-04-21       Impact factor: 12.079

4.  An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Tuscan; J William Harbour
Journal:  J Mol Diagn       Date:  2010-04-22       Impact factor: 5.568
  4 in total
  1 in total

1.  Salvage proton beam therapy for recurrent iris melanoma: outcome and side effects.

Authors:  Aline I Riechardt; Julian P Klein; Dino Cordini; Jens Heufelder; Matus Rehak; Ira Seibel; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-20       Impact factor: 3.117
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.